EPIRUBICIN HYDROCHLORIDE

LOE Approaching

epirubicin hydrochloride

NDAINTRAVENOUSPOWDER
Approved
Sep 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3

Mechanism of Action

agent. Although it is known that anthracyclines can interfere with a number of biochemical and biological functions within eukaryotic cells, the precise mechanisms of epirubicin's cytotoxic and/or antiproliferative properties have not been completely elucidated. Epirubicin forms a complex with DNA…

Indications (1)

Clinical Trials (3)

NCT05121350Phase 3Unknown

A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma

Started Mar 2022
NCT04736394Phase 3Unknown

A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients

Started Sep 2021
NCT04490993Phase 3Unknown

Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients

Started Mar 2017